EP
FENC icon

Essential Partners’s Fennec Pharmaceuticals FENC Stock Holding History

Essential Partners’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$860 Buy
80
+42
+111% +$343 ﹤0.01% 2304
2026
Q1 		$234 Buy
38
+14
+58% +$108 ﹤0.01% 2581
2025
Q4 		$185 Hold
24
– – ﹤0.01% 2445
2025
Q3 		$225 Hold
24
– – ﹤0.01% 2378
2025
Q2 		$199 Buy
+24
New +$164 ﹤0.01% 1943

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PCA
Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Essential Partners's FENC Position: Q2 2026 in Review

Essential Partners increased its Fennec Pharmaceuticals (FENC) stake by 111% in Q2 2026, buying an estimated $343 and bringing the position to 80 shares worth $860. The position accounts for ﹤0.01% of the portfolio, ranked #2304.

Essential Partners first reported a position in FENC in Q2 2025 and has held it in 5 quarters since. 105 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

  • Essential Partners held 80 shares of Fennec Pharmaceuticals worth $860 as of Q2 2026.
  • Essential Partners bought 42 Fennec Pharmaceuticals shares in Q2 2026, an estimated $343.
  • Fennec Pharmaceuticals made up ﹤0.01% of Essential Partners's portfolio in Q2 2026, its #2304 holding.
  • Essential Partners first reported a position in Fennec Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • 105 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Essential Partners's 13F filing for Q2 2026, filed 10 Aug 2026.